PT-141 before and after claims: what the evidence shows

Last updated 2026-07-25

What do people mean by PT-141 before and after?

When people search "before and after" for most drugs, they mean a photo: skin, weight, muscle. PT-141 doesn't work that way. Bremelanotide acts on melanocortin receptors in the brain, not on blood vessels or tissue, so there's no visible before and after in the way there is with, say, a filler injection or a weight loss drug ^[1]. What people actually mean when they ask this about PT-141 is: did my desire change, and how would I know. That's a fair question, and it has a real answer from clinical trials, just not a photographic one. The honest version of "before and after" here is a symptom score. The key trials used a tool called FSDS-DAO (Female Sexual Distress Scale-Desire/Arousal/Orgasm) and the FSFI (Female Sexual Function Index) desire domain to track change over 24 weeks ^[2]. Those are questionnaires, not photos. That's genuinely the right way to measure a drug that works on desire and distress rather than tissue.

What did the phase 3 trials actually measure as "improvement"?

The two main trials (known together as the RECONNECT studies) enrolled premenopausal women with hypoactive sexual desire disorder (HSDD) and randomized them to self-administered bremelanotide or placebo, dosed as needed before anticipated sexual activity ^[2]. The co-primary endpoints were change in the desire domain of the FSFI and change in the distress score from the FSDS-DAO. Across the two trials, bremelanotide produced statistically significant improvement over placebo on both measures ^[2]. A subgroup analysis of the RECONNECT data confirmed the effect held up across variables like age, menopausal transition status, and baseline desire severity, without one group driving the whole result . That's the real "before and after": a validated distress and desire score, self-reported over months, in a randomized comparison against placebo. It is not a single dramatic before-and-after moment. A phase 2b dose-ranging study that came before the phase 3 program used "responder" analysis, meaning it counted how many women hit a threshold of meaningful improvement rather than just averaging scores. That paper reported responder rates that supported moving forward with the 1.75 mg dose used in the approved product .

How big is the actual effect size, in plain numbers?

This is the part most marketing skips. The effect exists, but it is small in absolute terms, and more than one paper has said so directly. A 2024 reanalysis of the phase 3 data titled "Small Effects, Questionable Outcomes" reexamined the trial results and concluded the clinically meaningful benefit over placebo was modest, raising questions about how much of the group-level improvement actually matters to an individual woman . A separate 2021 reanalysis in the same journal made a similar point about how the trials defined and measured responder status . A UK drug bulletin review, comparing bremelanotide to flibanserin (the other FDA-approved HSDD drug), argued that regulatory approval doesn't necessarily mean the effect is large, calling out what it termed a "fallacy of regulatory precedent" in how these drugs get compared to each other rather than to a clean placebo bar . Here's the useful, non-hyped framing: some women in the trials had a clear, measurable improvement in desire and reduction in distress. Many did not. Nobody has a way to predict in advance which group you'll land in, and no paper in this evidence base claims otherwise.

What does a realistic PT-141 before and after actually look like?

Based on the trial design, not testimonials, a realistic account of "before and after" reads like this: before, a woman scores high on the FSDS-DAO distress scale and low on the FSFI desire domain. After roughly 24 weeks of as-needed dosing, her distress score drops and her desire domain score rises, by an amount that reaches statistical significance at the group level ^[2]. That's genuinely different from what a lot of online chatter implies, which is instant, dramatic arousal within an hour of injection. The drug can produce a physical response (some women report increased genital arousal sensation within a few hours), but the FDA-approved indication and the trial endpoints are about desire and distress over weeks, not a single-dose sexual performance event ^[3]. For context on the individual dose: bremelanotide is self-injected subcutaneously about 45 minutes before anticipated sexual activity, with a maximum of one dose in 24 hours and no more than 8 doses a month ^[3]. If you're mapping out what a single dose feels like versus what months of use look like, our guide to PT-141 dosage breaks down the practical side, and PT-141 cycle length covers how the monthly cap plays into realistic expectations.

Why is PT-141's mechanism different from Viagra-type drugs?

This is the single most useful thing to understand before judging any before-and-after claim. Sildenafil and its relatives work on blood vessels; they increase blood flow to genital tissue by blocking an enzyme called PDE5. That's a local, vascular mechanism, and it's why those drugs can produce a fast, visible physical effect. Bremelanotide works differently. It's a melanocortin receptor agonist that acts in the brain, primarily thought to work through MC4R pathways involved in the neurobiology of sexual desire . A 2022 review in CNS Spectrums specifically framed bremelanotide's action as central, not vascular, distinguishing its mechanism from PDE5 inhibitors used for erectile dysfunction . Because the mechanism is central, the expected "before and after" is a change in wanting, not a change in blood flow to a specific area. That distinction explains why bremelanotide doesn't produce the same immediate, localized physical signal that vascular drugs do, and why judging it by that standard sets up unrealistic expectations. For background on the receptor biology itself, see our overview of the PT-141 peptide. The melanocortin system bremelanotide touches also has roles well beyond sexual desire, including appetite and metabolism regulation, which is part of why researchers have studied related melanocortin-4 receptor agonists for metabolic disorders too ^[4].

What side effects show up alongside the "after" in real trial data?

Any honest before-and-after discussion has to include what happens in between, because bremelanotide's side effect profile is common enough that it shapes the real-world experience. Across the clinical development program, a pooled safety analysis found nausea was the most frequently reported adverse event, affecting roughly 40% of bremelanotide users in some trial data, along with flushing and headache as other common complaints ^[5]. These aren't rare footnotes. Nausea in particular is common enough that patients should expect it, not be surprised by it. | Side effect | Frequency reported in trials |

Does PT-141 cause weight loss as a visible "after" effect?

Some before-and-after claims online lump in weight change, likely because bremelanotide touches the same melanocortin system involved in appetite regulation. The actual data here is limited and specific. Two phase 1 randomized controlled trials looked at bremelanotide's effect on body weight in obese women and found measurable weight loss in the treatment group, but that data comes from phase 1 studies designed around a different population and endpoint than the phase 3 HSDD trials, and Vyleesi is not FDA-approved as a weight loss drug . Do not read this as evidence that Vyleesi produces weight loss in the general population using it for HSDD; that's a different question the approved product hasn't been tested for. If someone shows you a before-and-after claiming visible body composition change from PT-141, that claim is not supported by the trials that led to FDA approval, and it conflates a separate research question with the approved indication ^[3].

How long does it take to see results, and do they last?

In the main trials, the meaningful desire and distress score changes were assessed over a 24-week treatment period, meaning the trial's definition of "after" is months of use, not a single dose ^[2]. That doesn't mean nothing happens on day one; some women report a subjective arousal response within hours of an individual dose, but the FDA-approved efficacy data specifically measures cumulative change in desire and distress over time. On the single-dose side, bremelanotide has a plasma half-life of roughly 2 to 4 hours (reported across pharmacokinetic literature), meaning any single-dose effect from one injection is not expected to persist for days ^[3]. If you want a fuller pharmacokinetic breakdown, see our page on PT-141 half life. The dosing structure (no more than one dose per 24 hours, capped at 8 per month) means the trial's "after" picture reflects a pattern of intermittent use over weeks, not a cumulative buildup like a daily oral medication ^[3].

How does bremelanotide's effect size compare to flibanserin?

Flibanserin (Addyi) is the other FDA-approved drug for HSDD, and comparisons between the two come up constantly in before-and-after discussions, so it's worth being specific. A drug bulletin review directly comparing the two argued that neither drug has a dramatically large effect size, and cautioned against assuming FDA approval for one implies proof of superior real-world benefit over the other; the review specifically used the phrase "fallacy of regulatory precedent" to describe over-reliance on the fact that a similar drug was already approved . That's a useful corrective for anyone assuming approval equals a big, obvious effect. Mechanistically, the two drugs also don't work the same way. Flibanserin is a daily oral serotonin receptor modulator, while bremelanotide is an as-needed injectable melanocortin receptor agonist ^[3]. If you're weighing the two, understand that neither has trial data suggesting a large, uniformly reliable before-and-after effect, and both come with their own side effect tradeoffs (flibanserin carries alcohol interaction warnings; bremelanotide carries nausea and blood pressure considerations) [2, 21].

Are online PT-141 before and after testimonials reliable?

Be skeptical of dramatic personal testimonials, especially ones describing PT-141 as producing an immediate, powerful arousal event similar to a vascular drug. That description doesn't match the trial evidence or the mechanism. A 2023 evaluation in Expert Opinion on Pharmacotherapy specifically reviewed the bremelanotide injection's clinical trial data and noted the effect size, while statistically real, is modest at the individual level, consistent with the reanalyses discussed earlier ^[6]. Independent reanalyses of the same phase 3 data have gone further, questioning whether the group-level statistical significance translates into a change most individual patients would call meaningful [20, 23]. None of this means the drug doesn't work. It means the honest answer is: some benefit, on average, over placebo, measured through validated desire and distress scales over months, with common nausea and flushing along the way, not a guaranteed dramatic transformation from one injection.

What should you realistically expect if you start PT-141?

Expect nausea, possibly flushing and a headache, especially with your first few doses ^[5]. Expect to track how you feel over weeks, using something like the mental equivalent of the FSDS-DAO or FSFI desire questions, rather than expecting a single dramatic moment. Expect that roughly a quarter of women in the main trials reported meaningful desire improvement compared to about a sixth on placebo, a real gap but not an overwhelming one ^[2]. Expect to discuss blood pressure history with your prescriber before starting, given the documented transient blood pressure increases . And expect that this is a prescription decision that should go through a clinician who can review your full history, not something to self-diagnose from a before-and-after photo online. Bremelanotide is FDA-approved specifically for premenopausal women with acquired, generalized HSDD, and use outside that indication hasn't been established by the trial data ^[3]. If you're already working with a prescriber and want the product itself, Bremelanotide Rx works with a provider-reviewed pathway and names a fulfilling pharmacy partner as part of that process. We don't compound or manufacture anything ourselves. We cover the evidence so you can have an informed conversation with whoever prescribes it.

Frequently asked questions

What counts as a real "before and after" for PT-141?

A real before-and-after is a change in validated desire and distress scores (like the FSFI desire domain and FSDS-DAO) measured over about 24 weeks in clinical trials, not a photo or an instant physical effect ^[11]. Roughly 25% of women on bremelanotide showed meaningful improvement versus about 17% on placebo in the main trials ^[11].

Does PT-141 work like Viagra, with a visible fast effect?

No. Sildenafil works on blood vessels to increase local blood flow; bremelanotide works centrally on melanocortin receptors in the brain tied to desire, a mechanistically different pathway ^[18]. That means PT-141's expected effect is a shift in wanting over time, not a fast, localized vascular change you'd see or feel immediately the way you would with a PDE5 inhibitor.

How common is nausea with PT-141, and does it fade?

Nausea was the most frequently reported side effect across the bremelanotide clinical development program, affecting a large share of users, particularly with early doses ^[2]. Trial reporting patterns suggest it's often worse with the first dose, though the pooled safety data doesn't guarantee it resolves for every user.

Can PT-141 cause weight loss as part of its "after" effect?

Two phase 1 trials in obese women found measurable weight loss with bremelanotide, but this data is from an early-phase study population different from the HSDD trials, and Vyleesi is not FDA-approved for weight loss ^[26]. Don't interpret weight change claims as part of the approved product's expected effect.

How long until you see results from PT-141?

The main trials measured meaningful change over a 24-week treatment period using desire and distress questionnaires, so the clinically validated "after" picture is months of use, not one dose ^[11]. Some users report a subjective single-dose arousal sensation within hours, but that's separate from the trial's efficacy endpoint.

Is the PT-141 effect size actually large?

No, multiple independent reanalyses describe the effect as small to modest at the individual level, even though it reached statistical significance at the group level in the phase 3 trials [20, 23]. A 2024 paper specifically titled its reanalysis "Small Effects, Questionable Outcomes" to make this point ^[20].

Is PT-141 better than flibanserin (Addyi)?

Neither drug has a dramatically large effect size in trials, and a drug bulletin review cautioned against assuming FDA approval alone proves one is clearly superior to the other, a pattern it called a "fallacy of regulatory precedent" ^[16]. They also work differently: flibanserin is daily and oral, bremelanotide is as-needed and injectable ^[4].

Does blood pressure matter for PT-141 before and after outcomes?

Yes. Bremelanotide can cause transient increases in blood pressure, which is a specific clinical consideration for women with uncontrolled hypertension or cardiovascular disease ^[21]. This should be discussed with a prescriber before starting, since it affects candidacy, more than side effect tolerance.

How many doses of PT-141 can you use per month?

The FDA label allows a maximum of one dose in 24 hours and no more than 8 doses per month ^[4]. This dosing cap shapes what a realistic "before and after" timeline looks like, since it's intermittent use across weeks rather than daily accumulation.

Who was actually studied in the PT-141 before-and-after trial data?

The main RECONNECT trials enrolled premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) ^[11]. Vyleesi's FDA approval is specific to that population, so before-and-after claims from outside that group (postmenopausal women, men, or non-HSDD use) aren't supported by the efficacy data ^[4].

Are PT-141 before-and-after photos or visible results a real thing?

Not in the way photos work for skin or weight loss products. Bremelanotide's mechanism is central, acting on brain receptors tied to desire, not on visible tissue, so there's nothing photographic to compare ^[18]. The meaningful "after" is a validated questionnaire score change, not an image.

What percentage of women respond to PT-141 in clinical trials?

In the phase 3 RECONNECT trials, about 25% of women on bremelanotide reported a meaningful increase in desire compared to about 17% on placebo, a real but modest difference ^[11]. A phase 2b dose-ranging study used a separate responder-threshold analysis that supported the 1.75 mg dose ultimately approved ^[22].

Sources

1. Obstetrics and Gynecology, 2019 (PMID 31599840): Reports the phase 3 RECONNECT trial results, including desire and distress score improvement rates versus placebo.
2. Journal of Women's Health, 2022 (PMID 35147466): Pooled safety analysis showing nausea, flushing, and headache as the most common adverse events across the bremelanotide development program.
3. Drugs, 2019: Bremelanotide: First Approval (PMID 31429064): Describes FDA approval details, dosing regimen (one dose per 24 hours, max 8 per month), and approved indication for premenopausal HSDD.
4. Nature Reviews Endocrinology, 2023 (PMID 37365323): Describes the central melanocortin system's broader role in metabolic regulation beyond sexual desire.
5. Current Topics in Medicinal Chemistry, 2007 (PMID 17584134): Describes melanocortin receptor agonists' mechanism as central rather than acting on peripheral tissue.
6. Expert Opinion on Pharmacotherapy, 2023 (PMID 36242769): Evaluates bremelanotide injection clinical trial data and characterizes the effect size as modest at the individual level.
7. Drug and Therapeutics Bulletin, 2021 (PMID 34642243): Compares bremelanotide and flibanserin, arguing against assuming regulatory precedent proves superior real-world benefit.
8. CNS Spectrums, 2022: Neurobiology of Bremelanotide (PMID 33455598): Frames bremelanotide's mechanism as central, distinct from vascular PDE5 inhibitor drugs.
9. Journal of Sex Research, 2024: Small Effects, Questionable Outcomes (PMID 36809187): Reanalysis of phase 3 bremelanotide data concluding the clinically meaningful benefit over placebo is modest.
10. Medicina (Kaunas), 2022: Management of Hypertension with Female Sexual Dysfunction (PMID 35630054): Notes bremelanotide can cause transient increases in blood pressure, relevant to cardiovascular screening before use.
11. The Journal of Sexual Medicine, 2019: Responder Analyses from Phase 2b (PMID 31277966): Reports responder-threshold analysis from the phase 2b dose-ranging study that supported the approved 1.75 mg dose.
12. Journal of Sex Research, 2021: Re-Analyzing Phase III Bremelanotide Trials (PMID 33678061): Independent reanalysis questioning how phase 3 trials defined and measured meaningful responder outcomes.
13. Diabetes, Obesity and Metabolism, 2022: Effect of Bremelanotide on Body Weight (PMID 35170192): Reports measurable weight loss in obese women in two phase 1 randomized controlled trials of bremelanotide.